Abstract
The apolipoprotein E (APOE) is a well-established risk factor for late-onset Alzheimer’s disease (AD). Several studies have attempted to confirm the association between the polymorphism located at position −491 in the transcriptional regulatory region of the APOE gene and AD. We examined in 85 AD patients and 90 control subjects of a Tunisian population the potential involvement of this polymorphism as a risk factor for AD, either through an independent effect or through interaction with the existing APOE ε4 allele risk. The T allele frequency was significantly higher in the AD patients group (45.3 %) than in the controls group (32.78 %) and may possibly constitute a significant risk factor for AD. The APOE ε4 allele did not influence the distribution of the −491 polymorphism after stratification.
Similar content being viewed by others
References
Valenza A, Bizzarro A, Marra C, Lauria A, Guglielmi V, Rossi C, Tiziano FD, Brahe C, Masullo C (2010) The APOE −491A/T promoter polymorphism effect on cognitive profile of Alzheimer’s patients. Neurosci Lett 472(3):199–203. doi:10.1016/j.neulet.2010.02.004
Lynch CA, Brazil J, Cullen B, Coakley D, Gill M, Lawlor BA, Hawi Z (2008) Apolipoprotein E promoter polymorphisms (−491A/T and −427T/C) and Alzheimer’s disease: no evidence of association in the Irish population. Ir J Med Sci 177(1):29–33. doi:10.1007/s11845-007-0098-7
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921–923
Xin XY, Ding JQ, Chen SD (2010) Apolipoprotein E promoter polymorphisms and risk of Alzheimer’s disease: evidence from meta-analysis. J Alzheimers Dis 19(4):1283–1294. doi:10.3233/jad-2010-1329
Rassas AA, Mrabet Khiari H, Hadj Fredj S, Sahnoun S, Batti H, Zakraoui NO, Cherif A, Anane N, Ben Ali N, Messaoud T, Mrabet A (2012) High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population. Neurol Sci 33(1):33–37. doi:10.1007/s10072-011-0663-8
Association AP (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34(7):939–944
Bienvenu T, Meunier C, Bousquet S, Chiron S, Richard L, Gautheret-Dejean A, Rouselle JF, Feldmann D (1999) Different procedures for the isolation of DNA from blood samples. Ann Biol Clin (Paris) 57(1):77–84
Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31(3):545–548
Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Luna JL (2001) The –491TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer’s disease. Neurosci Lett 304(3):204–208
Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F (1998) Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 421(2):105–108
Toji H, Maruyama H, Sasaki K, Nakamura S, Kawakami H (1999) Apolipoprotein E promoter polymorphism and sporadic Alzheimer’s disease in a Japanese population. Neurosci Lett 259(1):56–58
Chen L, Baum L, Ng HK, Chan LY, Sastre I, Artiga MJ, Valdivieso F, Bullido MJ, Chiu HF, Pang CP (1999) Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer’s disease. Neurosci Lett 269(3):173–177
Roks G, Cruts M, Bullido MJ, Backhovens H, Artiga MJ, Hofman A, Valdivieso F, Van Broeckhoven C, Van Duijn CM (1998) The −491A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer’s disease. Neurosci Lett 258(2):65–68
Helisalmi S, Hiltunen M, Valonen P, Mannermaa A, Koivisto AM, Lehtovirta M, Ryynanen M, Soininen H (1999) Promoter polymorphism (−491A/T) in the APOE gene of Finnish Alzheimer’s disease patients and control individuals. J Neurol 246(9):821–824
Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, Mohr M, Cecyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, Amouyel P, Chartier-Harlin MC (1998) Pronounced impact of Th1/E47cs mutation compared with −491AT mutation on neural APOE gene expression and risk of developing Alzheimer’s disease. Hum Mol Genet 7(9):1511–1516
Casadei VM, Ferri C, Veglia F, Gavazzi A, Salani G, Cattaneo M, Sorbi S, Annoni G, Licastro F, Mariani C, Franceschi M, Grimaldi LM (1999) APOE −491 promoter polymorphism is a risk factor for late-onset Alzheimer’s disease. Neurology 53(8):1888–1889
Ahmed AR, MacGowan SH, Culpan D, Jones RW, Wilcock GK (1999) The −491A/T polymorphism of the apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer’s disease. Neurosci Lett 263(2–3):217–219
Lambert JC, Mann D, Goumidi L, Harris J, Amouyel P, Iwatsubo T, Lendon C, Chartier-Harlin MC (2001) Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer’s disease. Lancet 357(9256):608–609. doi:10.1016/s0140-6736(00)04063-0
Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC (1998) A new polymorphism in the APOE promoter associated with risk of developing Alzheimer’s disease. Hum Mol Genet 7(3):533–540
Nicodemus KK, Stenger JE, Schmechel DE, Welsh-Bohmer KA, Saunders AM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA, Martin ER (2004) Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease. Neurogenetics 5(4):201–208. doi:10.1007/s10048-004-0189-9
Roks G, Cruts M, Houwing-Duistermaat JJ, Dermaut B, Serneels S, Havekes LM, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM (2002) Effect of the APOE −491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: the Rotterdam study. Am J Med Genet 114(5):570–573. doi:10.1002/ajmg.10407
Yang JD, Feng GY, Zhang J, Cheung J, St Clair D, He L, Ichimura K (2003) Apolipoprotein E −491 promoter polymorphism is an independent risk factor for Alzheimer’s disease in the Chinese population. Neurosci Lett 350(1):25–28
Bizzarro A, Seripa D, Acciarri A, Matera MG, Pilotto A, Tiziano FD, Brahe C, Masullo C (2009) The complex interaction between APOE promoter and AD: an Italian case-control study. Eur J Hum Genet 17(7):938–945. doi:10.1038/ejhg.2008.263
Acknowledgments
This work was funded by the Ministry of Higher Education and Scientific Research in Tunisia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Achouri-Rassas, A., Hadj Fredj, S., Mrabet Khiari, H. et al. Association Between Alzheimer Disease and the −491T Allele of Regulatory Region Polymorphism of Apolipoprotein E in a Tunisian Population. Neurochem Res 39, 244–247 (2014). https://doi.org/10.1007/s11064-013-1213-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-013-1213-y